 Cellectar Biosciences Inc NASDAQ: CLRB has completed part A portion of a safety and tolerability study of iopofosine I-131 iopofosine in combination with external beam radiation EBRT in relapsed or refractory head and neck cancer. Related: Cellectar Receives 2M NIH Grant For Rare Lymphoma Study. 